[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363090-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-363090-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","clinical-versus-pathologic-staging-in-early-stage-non-small-cell-lung-cancer-original-article-open-access","Clinical Versus Pathologic Staging in Early-Stage Non-Small Cell Lung Cancer - Original Article - Open Access","","Accurate clinical staging of early-stage non-small cell lung cancer (NSCLC) is essential to guide treatment and serves as a quality indicator when compared with pathological staging. A retrospective review of 259 early-stage NSCLC patients assessed clinical versus pathologic concordance after multidisciplinary team (MDT) evaluation. Overall concordance occurred in 73%, with 18.9% showing clinical under-staging. Under-staging correlated with longer time from sentinel CT imaging to surgery and with visceral pleural, vessel, and lymphatic invasion, and increased mortality and recurrence at follow-up.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinical-versus-pathologic-staging-in-early-stage-non-small-cell-lung-cancer-original-article-open-access/363090/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinical-versus-pathologic-staging-in-early-stage-non-small-cell-lung-cancer-original-article-open-access/363090.png","ImageObject",300,407,{"name":42,"@type":43},"Đào","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s primary goal?","Question",{"text":63,"@type":64},"To compare clinical and pathological staging in early-stage NSCLC assessed by an established lung cancer MDT, with a focus on clinical under-staging.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many patients were included and what was the concordance rate?",{"text":68,"@type":64},"The cohort included 259 patients, with overall clinical and pathologic staging concordance occurring in 73% of cases.",{"name":70,"@type":61,"acceptedAnswer":71},"Which factors were associated with clinical under-staging?",{"text":72,"@type":64},"Clinical under-staging was associated with longer time between sentinel CT imaging and surgery and histopathologic evidence of visceral pleural, vessel, and lymphatic invasion.",{"name":74,"@type":61,"acceptedAnswer":75},"What impact did clinical under-staging have at follow-up?",{"text":76,"@type":64},"Clinically under-staged patients had a significantly increased risk of mortality and disease recurrence at follow-up.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},363090,1790471962,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Thoracic Cancer   \n ORIGINAL ARTICLE  OPEN ACCESS   \nClinical Versus Pathologic Staging in Early-Stage Non-Small Cell Lung Cancer Assessed by an Established Lung Cancer Multidisciplinary Meeting  \nJames Nolan1,2  | Theron Sather1 | Craig Hukins1,2 | Michelle Murphy1,2  \n1Respiratory Sleep and Mycobacterial Medicine, The Princess Alexandra Hospital, Woolloongabba, Queensland, Australia | 2School of Medicine, University of Queensland, Herston, Queensland, Australia  \nCorrespondence: James Nolan ([j.nolan@uq.edu.au](j.nolan@uq.edu.au))  \nReceived: 24 September 2025 | Revised: 11 February 2026 | Accepted: 27 February 2026  \nABSTRACT  \nIntroduction: Accurate clinical staging of early-stage non-small cell lung cancer (NSCLC) is critical to guide treatment recommendations. Clinical and pathological staging concordance for NSCLC is a quality indicator of lung cancer care. We compared clinical and pathological staging of early-stage NSCLC assessed by an established lung cancer multidisciplinary team (MDT), focusing on clinical under-staging.  \nMethod: Retrospective review of all patients with early-stage NSCLC referred by our lung cancer MDT for definitive surgical management between January 2019 and December 2023.  \nResults: The cohort included 259 patients. The median time from review by respiratory service and referral to cardiothoracic surgery was 82 (IQR 59–132) days. Time from MDT discussion to surgery was 28 (IQR 18–41.5) days. Overall clinical and pathologic staging concordance occurred in 73% of cases, with 18.9% of cases clinically under-staged. Factors associated with clinical under-staging were time between sentinel CT imaging and surgery (p = 0.01) and histopathologic evidence of visceral pleural (p = 0.003), vessel (p = 0.031) and lymphatic (p = 0.014) invasion. At follow-up there was a significantly increased risk of mortality (OR 2.06, p = 0.003) and disease recurrence (OR 2.06, p = 0.037) for clinically under-staged patients. Discrepancies which may have led to different treatment decisions occurred in 18 (7%) patients.  \nConclusion: For patients diagnosed with early-stage NSCLC referred for curative surgical management, disagreement between clinical and pathologic staging may be due to treatment delay and malignancy histopathological features. Clinically understaging increases risk of morbidity and mortality, which could be addressed through improved timeliness of care. Concordance of clinical and pathologic staging should be a routinely assessed benchmark for all lung cancer MDTs.  \n1 | Introduction  \nLung cancer is the fifth most diagnosed cancer in Australia and is the most common cause of cancer-related death, with incidence and prevalence continuing to increase [1] . Long-term outcomes are poor, with an overall five-year survival of 22%[2] . Surgical resection is the optimal treatment for appropriately staged non-small cell lung cancer (NSCLC), with approximately 20% of patients eligible for surgical management at diagnosis  \n[3, 4] . This proportion is anticipated to increase with the introduction of low-dose computed tomography (CT) lung-cancer screening programs [5] .  \nAccurate staging of NSCLC at the time of diagnosis provides valuable prognostic information, guides treatment decisions, and defines clinical trial eligibility [6] . Clinical staging is determined by a lung cancer multidisciplinary team (MDT) based on clinical evaluation, advanced imaging techniques, and targeted  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2026 The Author(s) . Thoracic Cancer published by John Wiley & Sons Australia, Ltd.  \nThoracic Cancer, 2026; 17:e70267 1 of 10  \n[https://doi.org/10.1111/1759-7714.70267](https://doi.org/10.1111/1759-7714.70267)  \nbiopsy results, a process which has advanced significantly in the","cbCaiiZ6hsnIaP1K","https://ap.wps.com/l/cbCaiiZ6hsnIaP1K","pdf",574433,"English","# Abstract\n# Introduction\n# Methods\n## Patient Cohort\n# Results\n# Conclusion","[{\"question\":\"What was the study’s primary goal?\",\"answer\":\"To compare clinical and pathological staging in early-stage NSCLC assessed by an established lung cancer MDT, with a focus on clinical under-staging.\"},{\"question\":\"How many patients were included and what was the concordance rate?\",\"answer\":\"The cohort included 259 patients, with overall clinical and pathologic staging concordance occurring in 73% of cases.\"},{\"question\":\"Which factors were associated with clinical under-staging?\",\"answer\":\"Clinical under-staging was associated with longer time between sentinel CT imaging and surgery and histopathologic evidence of visceral pleural, vessel, and lymphatic invasion.\"},{\"question\":\"What impact did clinical under-staging have at follow-up?\",\"answer\":\"Clinically under-staged patients had a significantly increased risk of mortality and disease recurrence at follow-up.\"}]","Clinical Versus Pathologic Staging in Early-Stage Non-Small Cell Lung Cancer - Original Article - Open Access | PDF",1790149952,25,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/003e721b3ca2d67f61ca6326c8c4bd59.webp",983,1291,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/218099f74fa4431d8ae1ee5bf1e4c001.webp",982,1290,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b91bca1485d7ac4af0d43053e41d317e.webp",981,1289,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78ecda7186815b9684fd4181d5d6813d.webp",980,1287]